Why EGFR Testing Matters Before Osimertinib (Tagrisso) Treatment
Written by Dr. Olivia Bennett, Senior Oncology & Clinical Research Content Specialist
Reviewed for medical accuracy under the Ivermectinkart Editorial Policy
Introduction
For many people with non-small cell lung cancer (NSCLC), choosing treatment now depends not only on where the cancer is located or how advanced it is, but also on specific genetic changes within the tumour. EGFR testing before osimertinib is important because Tagrisso (osimertinib) is a targeted therapy whose approved NSCLC uses include cancers with particular EGFR mutations. In the United States, FDA-approved indications include NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations in specified treatment settings. Testing can therefore help determine whether a person's tumour has a biomarker that makes osimertinib an appropriate treatment option under the relevant indication. EGFR testing can use tumour tissue, and approved testing approaches may also use circulating tumour DNA from a blood sample in certain settings. Understanding what an EGFR result means—and what a negative blood test may miss—is an important part of informed treatment planning.
What Is EGFR and Why Does It Matter in Lung Cancer?
EGFR stands for epidermal growth factor receptor. It is a protein involved in signalling that helps regulate cell growth and survival.
In some NSCLC tumours, the EGFR gene develops mutations that can make this signalling pathway abnormally active. These mutations can become important drivers of cancer growth.
This matters because certain medicines have been developed specifically to inhibit abnormal EGFR signalling. Osimertinib is one of these medicines and belongs to a group known as EGFR tyrosine kinase inhibitors, or EGFR TKIs.
Not every lung cancer has an actionable EGFR mutation. Testing the tumour's molecular characteristics is therefore necessary to distinguish cancers with relevant EGFR alterations from cancers driven by other biological mechanisms.
Which EGFR mutations are particularly important for osimertinib?
Two mutations are especially important across current FDA-approved osimertinib indications:
EGFR exon 19 deletions
EGFR exon 21 L858R substitution mutations
The FDA has authorized companion diagnostic tests that identify these mutations for Tagrisso treatment selection.
The T790M mutation also has an important historical and treatment-specific role. Osimertinib was initially developed for EGFR T790M-positive NSCLC that had progressed after earlier EGFR-targeted treatment, although its indications have since expanded substantially.
Important EGFR findings and what they can mean when considering osimertinib
EGFR finding | Why it matters | Important limitation |
Exon 19 deletion | Established sensitizing EGFR mutation relevant to approved osimertinib indications | Treatment setting and other clinical factors still matter |
Exon 21 L858R | Another established sensitizing mutation relevant to approved osimertinib indications | A positive result does not determine the entire treatment plan |
T790M | Historically important acquired resistance mutation and relevant to specific osimertinib testing indications | Its role depends on treatment history and clinical setting |
Other EGFR alterations | Some uncommon mutations may have different treatment implications | An EGFR-positive result does not automatically mean every EGFR-targeted drug is appropriate |
No mutation detected | Relevant EGFR alteration was not identified by that test/sample | A negative plasma result may require tissue testing when feasible |
Why Is EGFR Testing Before Osimertinib So Important?
EGFR testing before osimertinib helps establish whether the tumour carries the molecular target relevant to the drug's approved use. Without that information, clinicians may not know whether osimertinib is appropriately matched to the cancer's biology.
The FDA list of authorized companion diagnostic devices identifies several tests used to select people with NSCLC for Tagrisso based on relevant EGFR alterations.
Testing matches treatment to tumour biology
Traditional cancer treatment has often been selected using factors such as tumour type, stage, location, and a person's overall medical condition. Precision oncology adds another layer: biomarkers within the tumour.
EGFR testing asks a specific question—does this cancer contain an EGFR alteration for which an EGFR-targeted treatment may be appropriate?
For example, when the FDA approved osimertinib plus platinum-based chemotherapy in 2024 for first-line treatment of locally advanced or metastatic NSCLC, the indication specifically applied to tumours with EGFR exon 19 deletions or exon 21 L858R mutations detected by an FDA-approved test.
Testing can prevent inappropriate assumptions
Someone can have NSCLC without having an EGFR mutation relevant to osimertinib. Conversely, the absence of obvious clinical characteristics associated with EGFR-mutated cancer does not replace molecular testing.
Testing provides direct molecular information rather than relying on assumptions about who is likely to carry a mutation.
EGFR testing is not simply an additional laboratory test before osimertinib. It identifies whether the cancer carries a molecular alteration relevant to this targeted therapy, helping clinicians match treatment to the biology of the tumour rather than relying on symptoms or clinical characteristics alone.
How Is EGFR Testing Performed?
EGFR testing can be performed using tumour tissue or, with appropriate assays, circulating tumour DNA found in blood plasma. The appropriate approach depends on the clinical setting, available tissue, test being used, and other medical considerations.
Tumour tissue testing
Tumour tissue obtained during a biopsy or surgery can be analysed for genetic alterations.
Different laboratory technologies can detect EGFR mutations. These include targeted polymerase chain reaction (PCR) assays and next-generation sequencing (NGS), which can assess multiple genetic alterations simultaneously.
The FDA's current companion diagnostic list includes tissue-based tests authorized to identify EGFR exon 19 deletions and exon 21 L858R mutations for Tagrisso treatment selection.
Blood-based testing or liquid biopsy
Some EGFR tests analyse circulating cell-free DNA, including tumour-derived DNA released into the bloodstream. This is commonly described as a liquid biopsy.
Blood testing has practical advantages because collecting blood is less invasive than obtaining another tumour biopsy. FDA-authorized plasma companion diagnostics are available for identifying relevant EGFR alterations in NSCLC.
However, convenience does not make blood testing infallible.
What Does a Negative Blood EGFR Test Mean?
A negative plasma EGFR result does not necessarily prove that the tumour is EGFR-negative. A tumour may release too little detectable DNA into the bloodstream for a plasma assay to identify an alteration that is actually present.
This is an especially important limitation to understand before treatment decisions are made.
FDA information for Guardant360 states that a negative plasma result does not assure that the tumour is negative for the relevant genomic findings. When plasma testing does not identify the biomarker, FDA documentation recommends reflexing to tumour-tissue testing with an FDA-approved test when feasible.
The FDA information on an osimertinib companion diagnostic therefore provides an important practical lesson: a positive blood test can identify an actionable alteration, but a negative result may sometimes need confirmation using tumour tissue.
Why can blood and tissue results differ?
The amount of tumour DNA circulating in blood varies between people and cancers. Tumour burden, tumour location, biological behaviour, treatment history, and other factors can affect how much tumour-derived DNA reaches the bloodstream.
Tests also differ in the alterations they detect and their analytical characteristics.
For these reasons, “not detected” should be interpreted according to the specimen and assay used rather than automatically being treated as proof that no EGFR alteration exists.
Comparing tissue and blood-based EGFR testing before targeted treatment
Feature | Tumour tissue testing | Blood-based testing |
Sample | Tumour obtained through biopsy or surgery | Blood plasma |
What is analysed | DNA from tumour tissue | Circulating cell-free DNA, including tumour-derived DNA |
Major advantage | Directly examines tumour material | Less invasive and often easier to collect |
Important limitation | Adequate tumour tissue may not always be available | Tumour may release insufficient detectable DNA |
If relevant EGFR mutation is detected | Result can help guide treatment according to the test and clinical indication | Result can help guide treatment according to the test and clinical indication |
If result is negative | Interpretation depends on assay quality and tumour material | Negative result may need tissue testing when feasible |
Does EGFR Testing Matter at Different Stages of NSCLC?
Yes. EGFR status can be relevant in several different NSCLC treatment settings, and osimertinib's approved uses have expanded over time. The meaning of a positive result must therefore be interpreted together with disease stage, previous treatment, surgery status, and the exact indication being considered.
Early-stage disease after surgery
Osimertinib has an FDA-approved role as adjuvant treatment after tumour resection in selected people with NSCLC whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations.
In this context, EGFR testing helps identify whether the tumour carries the biomarker required for considering this targeted postoperative treatment.
Locally advanced disease
Osimertinib also has treatment roles in particular locally advanced EGFR-mutated NSCLC settings. The exact treatment sequence matters, so identifying EGFR status is only one part of deciding whether a specific indication applies.
Metastatic disease
For locally advanced or metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R mutations, osimertinib has established first-line treatment indications.
The FDA has also approved osimertinib in combination with platinum-based chemotherapy for first-line treatment of locally advanced or metastatic NSCLC with these mutations.
These examples show why an EGFR report should never be interpreted in isolation. The mutation, cancer stage, treatment history, other molecular findings, and person's overall clinical circumstances all contribute to treatment planning.
What Happens After an EGFR Test Result?
An EGFR result provides information for treatment planning rather than a treatment decision by itself. The oncology team interprets the exact alteration alongside cancer stage, previous treatments, pathology findings, other molecular biomarkers, medical history, and the regulatory indication relevant to the patient.
If an established sensitizing EGFR mutation such as an exon 19 deletion or exon 21 L858R mutation is detected, osimertinib may be considered in an appropriate clinical setting. FDA-authorized companion diagnostics specifically identify these mutations for Tagrisso treatment selection.
If plasma testing is negative, tissue testing may still be important when feasible because a negative blood result does not reliably exclude a tumour alteration.
If an uncommon EGFR alteration is found, interpretation may require additional care. Different EGFR mutations do not necessarily respond identically to the same targeted therapy, and evidence for one mutation should not automatically be applied to another.
What Should Patients Discuss With Their Oncology Team?
Before osimertinib treatment, it can be useful to understand exactly what was tested rather than simply hearing that a tumour is “EGFR-positive.”
Questions worth discussing include:
Which EGFR mutation was detected?
Was testing performed on tumour tissue, blood, or both?
Which molecular test was used?
If my blood test was negative, is tissue testing possible or necessary?
Does my EGFR mutation match the osimertinib indication being considered?
Were other clinically relevant lung-cancer biomarkers tested?
What is the goal of osimertinib in my situation?
What benefits, risks, monitoring, and alternatives should I understand before treatment?
These questions are particularly useful because molecular testing is only one component of treatment selection. Osimertinib can cause clinically important adverse effects, and prescribing decisions and monitoring should be managed by the treating oncology team.
Conclusion
EGFR testing before osimertinib is essential for identifying whether NSCLC carries a mutation relevant to this targeted treatment. Exon 19 deletions and exon 21 L858R mutations are particularly important across current approved indications, while the significance of other EGFR findings depends on the clinical setting. Tissue and blood-based testing can both provide useful molecular information, but a negative plasma result may not rule out an EGFR mutation and may warrant tissue testing when feasible.
If Tagrisso is being considered, discuss the exact EGFR result, testing method, treatment setting, expected benefits, risks, and alternatives with the oncology team. This information is educational and does not replace individualized cancer treatment advice.
Frequently Asked Questions
1. Do you need an EGFR test before taking Tagrisso?
For EGFR mutation-defined NSCLC indications, testing establishes whether the tumour carries the relevant EGFR alteration used to select patients for osimertinib. FDA-authorized companion diagnostics identify mutations such as exon 19 deletions and exon 21 L858R. Treatment decisions should be made by the oncology team.
2. Which EGFR mutations can make osimertinib relevant?
EGFR exon 19 deletions and exon 21 L858R substitutions are central to several current osimertinib indications. T790M has also been important in specific treatment settings. The significance of uncommon EGFR mutations varies, so the exact mutation—not simply an “EGFR-positive” label—matters.
3. Can EGFR testing be done with a blood test?
Yes. FDA-authorized liquid-biopsy tests can detect relevant EGFR alterations using circulating cell-free DNA from plasma. Blood sampling is less invasive than obtaining tumour tissue, but a negative plasma result does not necessarily mean the tumour lacks an EGFR mutation.
4. What happens if a liquid biopsy is EGFR-negative?
A negative liquid-biopsy result may be a false negative because some tumours release insufficient detectable DNA into the blood. FDA companion-diagnostic information recommends tissue testing after a negative plasma result when feasible. The oncology team can determine the appropriate next step.
5. Does being EGFR-positive automatically mean Tagrisso will work?
No. The exact EGFR mutation and clinical treatment setting matter, and no cancer treatment is guaranteed to work. EGFR results must be considered with disease stage, previous therapy, other tumour characteristics, overall health, and the approved indication when deciding whether osimertinib is appropriate.
6. Is EGFR testing only important in metastatic lung cancer?
No. EGFR testing can also affect treatment decisions in earlier and locally advanced NSCLC settings. Osimertinib has approved uses across specific disease settings, so molecular results need to be interpreted together with stage, surgery status, previous therapy, and other clinical information.
Comments